The initial visit includes intake, baseline bloodwork as clinically indicated, an honest discussion of evidence quality and realistic expectations, and protocol design based on individual goals and clinical profile
Key benefits: Active, methylated vitamins: L-5-MTHF (folate) and methylcobalamin (B12) for immediate bioavailability
What we handle: All PA types: prospective, concurrent, retrospective, urgent, emergency, and drug/medication PAs Payer portal submissions across 50+ EHR systems including Epic, Cerner, Athenahealth, eClinicalWorks, NextGen, and more Concurrent review tracking with automated deadline alerts Denial follow-up, peer-to-peer coordination, and formal appeals Eligibility verification and PA requirement checks before submission State-specific compliance for AZ (AHCCCS/WISeR), CO (ColoradoPAR/HCPF), WA (HCA/ProviderOne/WISeR), and all 50 states By the numbers: $399/week (volume discounts to $299/week) with no benefits overhead, no hidden fees 99.2% clean claim rate across 800+ providers 48-72 hour onboarding from signed agreement to live support 70% cost savings compared to in-house PA staffing 50+ EHR platforms supported Compliance credentials: SOC 2 Type II, ISO 27001, HIPAA compliant, and MGMA Corporate Member
National Library of Medicine) Subcutaneous (SQ) injections: technique, site selection, and procedure Frontiers in Pharmacology DSIP fusion peptides crossing the blood-brain barrier and efficacy in insomnia models European Neurology (PubMed) Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic pain episodes European Neurology (PubMed) DSIP in the treatment of withdrawal syndromes from alcohol and opiates Johns Hopkins Arthritis Center How to give a subcutaneous injection: site rotation and best practices Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
If it is necessary it can be administered up to 1 tablet 3 times a day
And importantly, the large 2025 Phase 3 GLP-1 Parkinsons trial failed to show meaningful disease modification compared to placebo
